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A Single Intramuscular Vaccination of Mice with the HSV1 VC2 Virus with Mutations in the Glycoprotein K and the
Membrane Protein UL20 Confers Full Protection against
Lethal Intravaginal Challenge with Virulent HSV-1 and
HSV-2 Strains
Brent A. Stanfield, Jacque Stahl, Vladimir N. Chouljenko, Ramesh Subramanian, Anu-Susan Charles,
Ahmad A. Saied, Jason D. Walker, Konstantin G. Kousoulas*
Division of Biotechnology & Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge,
Louisiana, United States of America

Abstract
Herpes Simplex Virus type-1 (HSV-1) and type-2 (HSV-2) establish life-long infections and cause significant orofacial and
genital infections in humans. HSV-1 is the leading cause of infectious blindness in the western world. Currently, there are no
available vaccines to protect against herpes simplex infections. Recently, we showed that a single intramuscular
immunization with an HSV-1(F) mutant virus lacking expression of the viral glycoprotein K (gK), which prevents the virus
from entering into distal axons of ganglionic neurons, conferred significant protection against either virulent HSV-1(McKrae)
or HSV-2(G) intravaginal challenge in mice. Specifically, 90% of the mice were protected against HSV-1(McKrae) challenge,
while 70% of the mice were protected against HSV-2(G) challenge. We constructed the recombinant virus VC2 that contains
specific mutations in gK and the membrane protein UL20 preventing virus entry into axonal compartments of neurons,
while allowing efficient replication in cell culture, unlike the gK-null virus, which has a major defect in virus replication and
spread. Intramuscular injection of mice with 107 VC2 plaque forming units did not cause any significant clinical disease in
mice. A single intramuscular immunization with the VC2 virus protected 100% of mice against lethal intravaginal challenge
with either HSV-1(McKrae) or HSV-2(G) viruses. Importantly, vaccination with VC2 produced robust cross protective humoral
and cellular immunity that fully protected vaccinated mice against lethal disease. Quantitative PCR did not detect any viral
DNA in ganglionic tissues of vaccinated mice, while unvaccinated mice contained high levels of viral DNA. The VC2 virus
may serve as an efficient vaccine against both HSV-1 and HSV-2 infections, as well as a safe vector for the production of
vaccines against other viral and bacterial pathogens.
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factor to 30–50% of new HIV infections [12,13]. A successful
vaccination strategy against HSV-2 infection is predicted to
have a dramatic global impact on HIV spread, prevention of
genital clinical disease and neonatal infections [14–16]. Prior
HSV immunity may confer only partial protection against HSV
re-infection and the appearance of clinical disease symptoms
[2,17]. Adaptive immune responses, particularly tissue specific
CD4+ and CD8+ T cells are crucial for controlling HSV
infections and clearing the virus after initial infection. These T
cell responses are also important in containing the virus in a
latent state in ganglionic or dorsal neurons, as well as for
controlling the virus after reactivation from latency [18–24].
Humoral responses have also been implicated in playing an

Introduction
Genital herpes has a very high global prevalence and disease
burden. Recent seroprevalence studies for the years 2005–2010
indicate that 1 out of 2 adults in the United States ages 14–49
years old are latently infected with herpes simplex type-1 (HSV1) [1]. Most infected individuals experience frequent, but
asymptomatic episodes of virus shedding that contribute to
high virus transmission rates [2–4]. An increasing number of
HSV-1 rather than HSV-2 infections are being observed in
clinical cases involving genital infections [5]. Importantly,
genital HSV infection is considered a risk factor for acquiring
human immunodeficiency virus infection (HIV) [6–11], and in
some geographical areas HSV-2 infection may be a contributing
PLOS ONE | www.plosone.org
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vaccination of mice with the gK-null virus conferred significant
cellular immune responses and protection against intravaginal
challenge of mice with either virulent HSV-1(McKrae) or HSV2(G) viruses [54]. To further improve on this vaccination
approach, we constructed the VC2 mutant virus with specific
deletions within the genes coding for glycoprotein K (gK) and
UL20. The VC2 virus contains the gKD31-68 mutation that
prevents the virus from infecting ganglionic neurons after ocular
infection in mice [55]. In contrast to the gK-null virus that requires
replication in the complementing cell line VK302 that expresses
gK [54], the VC2 virus can replicate efficiently in infected Vero
cells achieving titers similar to that of the wild-type HSV-1(F)
parental virus in cell culture. Herein, we report that a single
intramuscular vaccination with the VC2 virus was very well
tolerated at a high infectious dose (107 PFU), produced a robust
humoral and cell-mediated immune response and conferred 100%
protection against lethal intravaginal challenge with either HSV-1
(McKrae) or HSV-2 (G) viruses.

important role in controlling HSV infectivity, spread, and the
rate of reactivation from latency [25–27].
A number of vaccine approaches and candidates have been
evaluated in laboratory animals and humans including purified
peptides, recombinant glycoprotein subunits, inactivated, live
attenuated, replication competent and replication defective whole
virus, as well as DNA-based vaccines administered via different
routes of immunization (reviewed in: [28–32] In a double-blind
controlled, randomized efficacy field trial of a HSV-2 glycoprotein
D (gD-2) subunit vaccine adjuvanted with A04 (Herpevac Trial) in
8323 women, it was found that the vaccine was 82% protective
against HSV-1 genital disease, but offered no significant protection
against HSV-2 genital disease [33]. This protection correlated
with induction of neutralizing antibody against gD-2, while
cellular immune responses did not appear to be involved in the
observed protection [34,35]. A newer subunit vaccine approach
currently in phase I/IIa clinical trials is based on an attempt to
generate a balanced T cell and antibody response through the use
of T-cell epitopes derived from the ICP4 protein and antibody
generated by the gD-2 glycoprotein in conjunction with the
proprietary adjuvant Matrix-M [30].
In principle, live attenuated vaccines have distinct advantages
over subunit and inactivated vaccines, primarily because replication of the pathogen allows for the entire repertoire of pathogenspecific antigen expression. Given the 83% nucleotide identity
shared by both HSV-1 and HSV-2 genomes [36], cross protective
immunity may be achieved by a single safe and efficacious vaccine
expressing a large enough repertoire of cross-protective antigens.
Attempts at generating a live attenuated HSV vaccine have
focused on the preparation of attenuated viruses that can generate
robust immune responses, while minimizing potential virulence in
the host. Generally, entire genes that play important roles in the
virus lifecycle have been deleted or otherwise modified to
attenuate the virus and allow a more robust production of
humoral and cellular immune responses. Viral genome modifications include deletions in glycoprotein E (gE) [37,38], multiple
deletions in c34.5, UL55-56, UL43.5, US10-12 [39], UL5, UL29,
UL42, ICP27 genes [40–43], deletion of ICP0- [44] and the UL9
gene [45–48]. Other live virus vaccines under study include the
HSV-1 virus CJ9-gD engineered to overexpress gD1 and having a
dominant negative mutation to prevent virus replication. This
vaccine strain has been reported to protect guinea pigs from HSV2 intravaginal challenge, with marked reduction in vital titer and
lesion formation [47].
Generation of a safe and effective replication competent HSV-1
virus is important to not only vaccinate against acquiring HSV
infection and reduce HIV prevalence, but also a safe vaccine
vector could be utilized for expression of heterologous antigens
from other pathogens. HSV has many non-essential genes and can
stably carry large fragments of foreign DNA. This genetic
flexibility is ideal for the expression of antigens specific to other
pathogens [49,50]. Recently, a recombinant HSV expressing
granulocyte monocyte colony stimulating factor (GM-CSF), a
potent chemokine functioning in the maturation of macrophages,
has been used in combination with other chemotherapeutics for
the treatment of squamous cell cancer of the head and neck with
promising phase I/II results [51]. FDA approval for this particular
HSV vaccine therapy for melanoma is expected to pave the way
for the use of live-attenuated HSV-based vectors for vaccination
against HSV and other pathogens.
Previously, we have shown that a gK-null virus was unable to
infect ganglionic neurons and establish latency after ocular
infection of mice [52,53]. We capitalized on the attenuated
properties of the gK-null virus and showed that intramuscular
PLOS ONE | www.plosone.org

Results
Construction and characterization of the VC2 vaccine
virus
The VC2 recombinant virus was constructed utilizing the twostep double-Red recombination protocol implemented on the
cloned HSV-1(F) genome [55] in a bacterial artificial chromosome
(BAC) plasmid [56], as we have described previously [57,58], and
detailed in the Materials and Methods section. The VC2 virus
contains the gKD31-68 deletion (37 aa; gK aa 31–68) in the amino
terminus of gK that prevents the virus from entering into
ganglionic neurons after infection via the ocular route [55], as
well as a deletion of the amino-terminal 19 amino acids of the
UL20 virus (Fig. 1A). Next generation whole genome sequencing
was performed to validate that only intended mutations were
induced into the HSV-1(F) BAC. A total sequence output of Q20
quality that is derived from the predicted per-base quality scores
and corresponds to an error rate of 1% generated 2666and 4436
coverage for the two biological replica samples sequenced. A total
of 37 nt changes and 13 of that caused aa differences were
detected in comparison to the Gene bank submission GU 734771
of human herpes virus type 1 (strain F, complete genome), as we
have reported previously for other HSV-1(F) BAC mutant viruses
[59]. Overall, there were no nucleotide changes between the
parental HSV-1(F) BAC and the derived VC2 mutant virus with
the exception of the engineered deletions within the UL20 and gK
genes.
We have previously shown that the amino termini of both gK
and UL20 interact with gB and that these interactions modulate
virus-induced cell fusion mediated by the gK/UL20 protein
complex [57,60,61] (Fig. 1B). The UL20D4-22 mutation does not
affect virus replication, although it produces a syncytial phenotype
(not shown). However, the simultaneous presence of the gKD31-68
and UL20D4-22 deletions produce non-syncytial plaques, which
were 30–40% smaller in size than those of the parental virus
(Fig. 2A). The VC2 virus replicated as efficiently as the parental
wild-type HSV-1(F) BAC virus at a MOI of 5. At low MOI (0.1),
VC2 replicated with slower kinetics, but achieved similar peak
virus titers by 36 hpi (Fig. 2B). The VC2 and HSV-1(F) BAC
viruses exhibited similar entry efficiencies into Chinese hamster
ovary (CHO) cells expressing the HSV-1 receptors Nectin-1, and
HVEM (Fig. 2C). Both HSV-1(F) and VC2 failed to enter into
paired immunoglobulin receptor-a (PILRa), expressing CHO
cells, as we have reported previously for HSV-1(F) in comparison
to HSV-1(McKrae) [62].
2
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Figure 1. Schematic of the construction of VC2. (A) The top line represents the prototypic arrangement of the HSV-1 genome, with the unique
long (UL) and unique short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions. Shown below are the expanded genomic
regions which encompass the open reading frames of UL20 and glycoprotein K. In black are the approximate deletions within their respective genes.
(B) A graphical depiction of the gK UL20 complex interacting with gB. Areas between the black lines on the graphical depiction represent the
aproximate location of the deletion in their respective genes.
doi:10.1371/journal.pone.0109890.g001

Figure 2. In-vitro analysis of the replication and entry characteristics of VC2 vs F BAC. (A) Plaque morphology of VC2 vs F BAC on Vero
cells 48 hours post infection visualized by IHC and developed with NovaRed substrate. (B) Growth curve representative of the replication kinetics of
VC2 vs F BAC at both and low (0.1) and high (5) MOI. Samples collected at times 0, 2, 4, 6, 9, 12, 18, 24, and 36 hours post infection titrated on Vero
cells. (C) Entry assay depicting VC-2 vs F BAC into Chinese hamster ovary (CHO) cells expressing known herpes virus entry receptors PILR-a, nectin 21,
HVEM, and NEO for a negative control.
doi:10.1371/journal.pone.0109890.g002

PLOS ONE | www.plosone.org

3

October 2014 | Volume 9 | Issue 10 | e109890

Live-Attenuated Vaccine for Genital Herpes

Vaccination and intravaginal challenge of VC2 vaccinated
mice with HSV-1(McKrae) and HSV-2(G) viruses
Initial safety experiments indicated that the VC2 virus did not
produce significant clinical disease symptoms after intranasal or
intramuscular injection of 107 PFU per mouse, and there was no
viral DNA detected by PCR in either dorsal or trigeminal ganglia
from these mice (not shown). The vaccine strategy involved
intramuscular injection of 107 PFU of the VC2 virus in each
mouse followed by treatment of mice at day 15 post vaccination
via intramuscular injection of Depo Provera, as described
previously [54], and intravaginal challenge with 106 PFU of either
HSV-1(McKrae) or HSV-2(G) viral strains at day 21 post
vaccination. VC2 vaccinated mice were monitored for clinical
disease symptoms and the body weights were also monitored daily.
No significant clinical disease symptoms were noted throughout
the 15 day observation period. Also, no significant differences in
body weights of vaccinated versus mock-vaccinated animals were
observed except on day 14 post vaccination (p,0.05) (Fig. 3A).
Following vaginal challenge with either HSV-1(McKrae) or HSV2(G), infected mice were observed daily for disease manifestations.
Clinical scores and weight measurement were recorded for all live
mice for fifteen days following challenge,. Mock-vaccinated
animals showed pronounced, time-dependent increase in clinical
disease symptoms and a significant concomitant decrease in weight
by day 5 post challenge (Fig. 3: B, C). Analysis of clinical scores
with the corresponding changes in weights of unvaccinated mice
revealed a strong correlation between increasing clinical scores
and decreasing body weights (Fig. 3D). This correlation analysis
revealed that the observed difference in vaccinated versus mockvaccinated animals on day 14 post vaccination was not indicative
of significant overall morbidity. Disease symptoms in the mildest
cases consisted primarily of hair loss, hunched posture and fur
ruffling (not shown). More advanced disease symptoms included
significant vaginal and peri-anal erythema and edema and
purulent discharge (Fig. 4). As noted previously [54], HSV1(McKrae) caused significant clinical disease approaching that
observed in HSV-2(G) infections (Fig. 4).
Vaccinated mice were completely protected against lethal
challenge. Mice in the mock-vaccinated group started dying on
day 6 for the HSV-1 challenged group, and day 7 in the HSV-2
challenged group. In both groups of mice, challenged with either
HSV-1 or HSV-2, protection against lethal challenge was
significantly higher in vaccinated than mock-vaccinated animals
(p,0.0001) (Fig. 5). Vaginal shedding was assessed for 4 days
following challenge. Significant reductions in virus shedding were
observed on all days post challenge in the HSV-1 (days 1, 2:
p = 0.0002; day 3: p = 0.008; day 4: p = 0.0244): and HSV-2 group
of mice (day 1: p = 0.0014; days, 3–4: p,0.0001). In both cases,
vaccinated animals did not shed any virus after day 4 post
challenge. Overall, lower viral titers were recovered from the
vaginas of the HSV-2 than the HSV-1 challenged mice (Fig. 6: A,
B).
To determine whether HSV-1 (McKrae), or HSV-2(G) were
able to infect ganglionic or dorsal root neurons and establish latent
infection, challenged mice were immunocompromised by injection
of cyclophosphamide followed by injection of dexamethasone at
100 days post challenge. No infectious virus was recovered from
vaginal swabs of vaccinated mice treated with cyclophosphamide
and dexamethasone which is known to chemically induce
reactivation of virus from latency [63]. Similarly, there was no
viral DNA detected for either HSV-1(McKrae) or HSV-2(G) in
the extracted neuronal tissues by virus type-specific quantitative
PCR (qPCR) for the vaccinated mice at the lowest possible
detection limit of approximately 3 viral genomes (see Materials
PLOS ONE | www.plosone.org

Figure 3. Pre and post challenge morbidity. (A) Pre challenge
percent change in weight in mock vs vaccinated animals. Percentages
normalized to the initial weight at day 0. ** p#0.01. Bars represent the
95% confidence interval about the mean. Statistical comparison
conducted by SAS using Proc Mixed Type 3 Tests of Fixed Effects. (B)
Clinical scoring of mice previously receiving mock IM vaccination or 107
PFU IM vaccination of VC2. Two groups (Mock and Vaccinated n = 10
each) received a intravaginal challenge of 106 PFU of HSV-2 (G) and 2
groups (Mock and Vaccinated n = 10 each) received a intravaginal
challenge of 106 PFU of HSV-1 (McKrae). Mice were scored on a scale of
0–6 (0 = no disease, 1 = ruffled fur and generalized morbidity, 2 = mild
genital erythema and edema, 3 = moderate genital inflammation,
4 = genital inflammation with purulent discharge, 5 = hind limb
paralysis, 6 = death). (C) Percent change in weights post challenge in
Mock vs vaccinated animals challenged with either HSV-1 (McKrae) or
HSV-2 (G). Percentages normalized to the initial weight at day 0. ** p#
0.01. Bars represent the 95% confidence interval about the mean.
Statistical comparison conducted by SAS using Proc Mixed Type 3 Tests
of Fixed Effects. (D) Correlation between percent change in weight VS.
Clinical score of unvaccinated mice Gaussian Approximation p,0.0001
Spearman r = 20.84108.
doi:10.1371/journal.pone.0109890.g003

and Methods section). In contrast, tissues from mock-vaccinated
animals revealed the presence of high copy numbers of either
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Figure 4. Pathogenesis post challenge. Disease pathology among mock (top two panels) and vaccinated (bottom two panels) animals
challenged with either HSV-1 (McKrae) or HSV-2 (G) 5 days post challenge. HSV-1(McKrae) and HSV-2(G) infected mice exhibited similar disease
progression and pathology in the mock groups (top two panels). Vaccinated mice (bottom two panels) did not exhibit any clinical disease over the
observation period post challenge. Mild disease symptoms included ruffled fur, hunching posture, inflammation and redness of vagina (top right).
More serious manifestations included purulent vaginal discharge (top left).
doi:10.1371/journal.pone.0109890.g004

lymphocytes from mock-vaccinated mice did not respond to the
pooled peptide stimuli (Fig. 8A). Additional analysis was performed by determining the relative levels of Th1/Th2 cytokines in
response to the peptide pool. Significant induction of IFNc,
TNFa, IL-4 and IL-5 were noted, while IL-2 was not significantly
induced in the vaccinated versus mock-vaccinated mice (Fig. 8:B–
F).

HSV-1(McKrae) or HSV-2(G) viral DNA in the respective animal
groups (Table 1).

VC2-induced humoral and cellular immune responses
To assess the relative levels of HSV-1 specific antibodies raised
by the VC2 vaccination a commercially available ELISA was
utilized to measure the relative quantity of HSV-specific IgG. In
this ELISA, plates were coated with HSV-1-infected cell extracts
and HSV-1 bound antibodies were quantified by colorimetry (see
Materials and Methods). All VC2 vaccinated mice produced
HSV-1-specific antibodies, while none of the mock-vaccinated
animals produced detectable anti-HSV antibodies (Fig. 7A). The
VC-2-induced antibodies were tested for ability to neutralize
HSV-1(McKrae) virus. Antisera from five vaccinated and mockvaccinated mice were individually tested at serial dilutions for
ability to neutralize the virus, as described in Materials and
Methods. Substantial neutralization of HSV-1(McKrae) was noted
at 1:160, 1:80, 1:40 and 1:20 dilutions of each mouse serum
(Fig. 7B). To further investigate the neutralization activities of
these sera, the 1:20 dilution was chosen to test for ability to
neutralize both HSV-1(McKrae) and HSV-2(G). Significant
differences were observed between the neutralization of HSV1(McKrae) and HSV-2(G) by sera of VC2-vaccinated animals in
comparison to the mock-vaccinated mice. However, no significant
differences were observed between the mock-vaccinated groups
(Fig. 7C).
To test for the generation of VC2-specific cellular immune
responses, a CFSE-membrane labeling assay was utilized to detect
cellular proliferation of CD4+ and CD8+ T cells in the presence of
a pool of specific peptides representing known or predicted CD4+
and CD8+ T epitopes (Table S1). Splenocytes from vaccinated
mice produced both CD8+ and CD4+ T cell proliferation, while
PLOS ONE | www.plosone.org

Discussion
Previous studies from our laboratory have focused on the role of
HSV-1 gK in neuronal entry and spread. Capitalizing on our
findings that gK is necessary for infection of ganglionic neurons
after ocular infection, we explored the use of a gK-null virus as a
potential vaccine for HSV-1 and HSV-2 genital infection. This
initial work showed that gK-null vaccination produced effective
strong cellular immune responses and provided significant
protection in mice [54]. However, replication of the gK-null virus
requires the use of a complementing cell line, negatively impacting
the possibility that this virus could be produced for human use. In
contrast, the VC2 engineered virus can efficiently replicate in
standard cell cultures, while retaining the in vivo avirulent
characteristics of the gK-null virus. The VC2 virus was highly
immunogenic and conferred 100% protection of vaccinated mice
against lethal intravaginal challenge with highly virulent HSV-1
and HSV-2 strains.

Construction of the VC2 virus
We have shown that gK forms a functional protein complex
with the UL20 membrane protein that is required for their
intracellular transport, cell-surface expression and ability to
modulate gB-mediate membrane fusion [61,64]. Modulation of

5
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Figure 5. Kaplan-Meier survival curves. Vaccinated and mockvaccinated mice in challenge groups were challenged thorough the
intra-vaginal route with 106 PFU of HSV-1 McKrae (A) or HSV-2G (B)
21 days post primary vaccination and observed for 14 days. One
hundred percent of the vaccinated animals in the HSV-1 and HSV-2
challenged group survived, while 100% of the mock-vaccinated animals
died. (A) A statistically significant difference was observed between the
vaccinated and mock-vaccinated groups (p,0.0001) using the GehanBreslow-Wilcoxin test. (B) A statistically significant difference was
observed between the vaccinated and mock-vaccinated groups (p,
0.0001) using the Gehan-Breslow-Wilcoxin test.
doi:10.1371/journal.pone.0109890.g005

Figure 6. Vaginal shedding post challenge. (A) HSV-1 shedding
post challenge in mock vs vaccinated animals. (B) HSV-2 shedding post
challenge in mock vs vaccinated animals. Significant differences in shed
titers noted as * p#0.05, ** p#0.01, or *** p#0.0001. Bars represent the
95% confidence interval about the mean. Statistical comparison
conducted by SAS using The Mixed Procedure Type 3 Tests of Fixed
Effects.
doi:10.1371/journal.pone.0109890.g006

culture (not shown). However, incorporation of the gKD31-68
mutation eliminated the UL20D4-22-induced cell fusion providing
additional support for our long-standing hypothesis that UL20 and
gK cooperate to regulate gB’s fusogenic properties primarily
through interactions of the amino-termini of gK and gB [57,60].
As expected the VC2 virus replicated efficiently in Vero cells in
comparison to its parental virus HSV-1(F), while it produced on
average smaller viral plaques as has been shown previously for the
gKD31-68 mutation in both the HSV-1(F) and HSV-1(McKrae)
genetic backgrounds [55,57]. Also, the VC2 virus efficiently
utilized the nectin-1 and HVEM receptors for virus entry except
the PILRa receptor, as we have shown previously for the HSV1(F) virus [62].

gB fusogenic properties is mediated via direct protein-protein
interactions between the gK and gB amino termini, as well as
between the gB carboxyl-terminus and the UL20 amino terminus
[57,60]. We constructed the VC2 virus under the hypothesis that
disruption of gK/UL20 interaction with gB will lead to viral
attenuation. This hypothesis was supported by the fact that
deletion of 37 aa from the amino terminus of gK prevented the
virus from infecting ganglionic neurons after ocular infection of
mice. Serial deletions of amino acids 4–22, 4–27, and 4–47 from
the amino terminus of the UL20 protein have revealed that amino
acids 4–27 are dispensable for virus replication in cell culture with
the 4–22 deletion producing similar virus titers to that of the HSV1(F) parental virus (Chouljenko and Kousoulas, unpublished).
Therefore, we chose to engineer the 4–22 UL20 deletion into the
VC2 virus providing an additional safety feature, since rescue of
the VC2 virus by a wild-type genome in vivo would require a
double recombination-rescue event to take place. Moreover,
disruption of the UL20 amino terminus would provide additional
dysregulation of gB functions, as evidenced by the fact that the
UL20D4-22 mutant virus caused virus-induced cell fusion in cell

PLOS ONE | www.plosone.org

Vaccination experiments
We have shown that HSV-1(F) BAC does not cause substantial
disease symptoms after ocular infection of mice, in contrast to the
highly virulent HSV-1(McKrae) strain, although both viruses are
readily transmitted to ganglionic neurons and establish latency
[55,65]. Consistent with these previously reported results, safety
experiments performed by intranasal infection with 106 PFU of
either HSV-1(F) BAC or VC2 viruses revealed no apparent
clinical symptoms and absence of detectable viral genomes in
6
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Table 1. qPCR of dorsal root ganglia from vaccinated animals.

HSV-1 Challenge

HSV-1 gD
6

HSV-2 gD

HSV-2 Challenge

HSV-1 gD

HSV-2 gD

Positive Control

.1.0 6 10

ND

Positive Control

ND

.1.0 6 106

161

ND

ND

171

ND

ND

162

ND

ND

172

ND

ND

163

ND

ND

173

ND

ND

164

ND

ND

174

ND

ND

165

ND

ND

175

ND

ND

166

ND

ND

176

ND

ND

167

ND

ND

177

ND

ND

168

ND

ND

178

ND

ND

169

ND

ND

179

ND

ND

170

ND

ND

180

ND

ND

qPCR results from sacral dorsal root ganglia excised from vaccinated mice challenged with either HSV-1 (McKrae) or HSV-2 (G). Positive controls were sacral dorsal root
ganglia excised from unvaccinated mice challenged with either HSV-1 (McKrae) or HSV-2 (G). Samples below the limit of detection are designated as ND. The qPCR
assays specific for either HSV-1 and HSV-2 viral DNA detected as low as 3 viral DNA copies/mL (see Materials and Methods).
doi:10.1371/journal.pone.0109890.t001

trigeminal ganglia. Similarly, infectious doses of up to 107 PFU of
either HSV-1(F) BAC or VC2 delivered intramuscularly did not
produce any significant clinical disease symptoms and there was
no viral DNA detected in either trigeminal or dorsal root ganglia
of infected mice. However, it is possible that very low numbers of
viral DNA were present in the tested tissues samples, since the
limit of qPCR detection was approximately 3 copies/ml. The
presence of high numbers of viral DNA in the positive control
sample versus the undetected levels of DNA in the vaccinated
animals support the hypothesis that very low amounts, if any of
challenging virus was able to infect ganglionic neurons and
establish latency.
Glycoprotein K has been associated with increased virulence
and immunopathogenesis. Specifically, ocular infection of mice
previously vaccinated with gK exacerbated corneal immunopathogenesis, while a HSV-1 virus expressing two copies of the gK
gene was significantly more virulent than the wild-type virus [66–
70]. Recently, we showed that the gKD31-68 mutation attenuates
the highly virulent ocular HSV-1(McKrae) strain and prevent
infection of trigeminal ganglionic neurons after ocular infection
[55]. The VC2 vaccine strain contains the gKD31-68 mutation,
which attenuates the virus and preventing efficient infection of
ganglionic neurons. Therefore, it is reasonable to assume that VC2
is substantially safer than HSV-1(F) BAC, since it contains double
gene deletions in gK and UL20 associated with defects in neuronal
entry.
In general, live-attenuated viral vaccines mimic natural
infections and induce more robust humoral and cellular immune
responses against a broad spectrum of viral proteins. In contrast,
subunit vaccines can only carry a limited number of immunogenic
epitopes and do not directly induce innate immune responses, as is
the case with live virus vaccines. Intramuscular immunization with
the VC2 virus produced neutralizing antibody against both HSV1(McKrae) and HSV-2(G) virus. HSV-1 and HSV-2 share a
relatively high degree of protein sequence homology and are
known to induce type-common antibodies (cross reactive between
HSV-1 and HSV-2) that recognize major antigenic viral
determinants, the majority of which constitute sequential and
conformational domains of viral glycoproteins [71,72]. Moreover,
pre-existing HSV-1 exposure is known to reduce the severity and
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duration of HSV-2 infection [29] suggesting the elicitation of typecommon immune responses.
Assessment of T cell responses was facilitated by the use of pools
of selected and well-characterized peptides representing gB and
gD-specific CD4+ andCD8+ T cell epitopes, as reported previously
[54], including few additional viral peptides (Table S1). Proliferation of T-cells cultured with pooled peptides is a direct measure of
memory T cells capable of recognizing the epitopes present in the
peptide pool only. As such, they are expected to underestimate the
overall T-cell response against the HSV proteome that is expressed
by the VC2 vaccine. As we reported previously, the most
prominent T cell response observed in gK-null vaccinated mice
was from gB-specific CD8+T cells (specifically peptide 161–176).
Interestingly in human patients, this particular T-cell epitope has
been identified as immunodominant, recalling the strongest HLADR-dependent CD4+ T-cell proliferation and IFN-c production in
contrast to other epitopes [73]. The gB (161–176) and gB (499–
506) peptide sequences are identical between HSV-1 and HSV-2,
therefore, we hypothesize that immune responses directed toward
these two epitopes may contribute to the observed cross-protection
against both HSV-1 and HSV-2 infections. In addition, most other
peptides utilized for the proliferation assays exhibited a high level
of amino acid conservation and homology in the HSV-1 and
HSV-2 proteomes suggesting that they may also be involved in the
induction of cross-protective immunity.
Intramuscular vaccination with the VC2 virus followed by intra
vaginal lethal challenge with either HSV-1 (McKrae) or HSV-2
(G) protected 100% of the vaccinated mice, while all mockvaccinated mice died. Importantly, infectious virus could not be
recovered after immunosuppression of vaccinated and challenged
mice and the ganglia of these mice did not contain detectable viral
DNA. Collectively these results and the observed rapid inhibition
of virus replication in infected vaginal tissues in vaccinated versus
mock-vaccinated mice, suggests that protection against the
challenging viruses was conferred largely by limiting virus
replication in infected vaginal tissues. A potential limitation of
the virus reactivation after immunosuppression assay is that
approximately 30% of latently-infected animals would be expected
to reactivate infectious virus production under similar immunosuppression conditions. In addition, although all immunosuppressed mice exhibited clear clinical signs of immunosuppression
7
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under these standard treatment procedures, verification of a
substantial reduction in blood lymphocytes would have provided
additional evidence of their immune status. Lastly, although qPCR
utilized in these studies is sensitive to 3 viral DNA copies per
sample, explant cultures of ganglionic tissues may recover very low
amounts of virus indicating the presence of low copy of viral DNA
in ganglionic neurons. Although not done in this study, it would be
of interest to test for virus in an extended explant assay to further
support our sensitive qPCR findings.
Adaptive immune responses are essential for providing protection against HSV-1 and HSV-2 infections [28,74,75]. Recently, it
was shown that HSV-2-specific CD8+ T cells generated after
chemo-attractant therapy given vaginally in mice mediate longlived protection against HSV-2 challenge [76]. Our observations
of the inhibition of viral replication in vaginal tissues within the
first 3–4 days post infection suggests that the induction of
neutralizing antibodies and the rapid local recruitment of cytotoxic
T-cells are sufficient to protect against HSV infection. This theory
is supported by the presence of neutralizing IgG antibodies and
the development of potent memory T cell pools in the vaccinated
mice. Additional studies are needed to assess the level of tissuespecific, intra-vaginal immunity to HSV-1 and HSV-2 infections
after a single dose of VC2.
Ideally, a live-attenuated vaccine could be used for both
prophylactic and therapeutic purposes. Elicitation of robust tissuespecific T-cell memory responses would confer substantial
advantage in limiting replication of reactivated virus, as well as
inhibiting secondary infections. It is also likely, that CD8+T cells
may prevent viral reactivation from latently infected neurons. The
VC2 virus could be effectively utilized as a vector for expression of
other viral and bacterial pathogens. VC2 expressed foreign
antigens may provide a strong adjuvant effect causing the
generation of protective adaptive immune responses against
mucosally transmitted pathogens such as HIV and Chlamydia
trachomatis.

Materials and Methods
This work was approved by the Louisiana State University
School of Veterinary Medicine IACUC protocol 13-011. Mice
were mildly anesthetized by inhalation of 2–3% isoflurane prior to
vaccination. Mice were euthanized by cervical dislocation.

Viruses
VC2 recombinant virus construction was performed using
double red recombination system in E. coli SW105 cells as
described previously [55]. Briefly, specific oligonucleotides designed to delete (aa 31–68) within the ORF encoding the HSV-1
gene UL53 (gK) were used first to generate the respective BAC
cloned into E. coli. After transfection of the Vero cells the
recombinant HSV-1 virus gK D31-68 was recovered. Fresh Vero
cells were infected with this virus and circular viral DNA was
isolated 6 hours post infection (hpi) using the method previously
described by Hirt et al.[77]. Virus DNA was electroporated into
SW 105 cells and a second round of recombination was performed
using specific oligonucleotides designed to delete (aa 4–22) within
the ORF encoding HSV-1 gene UL20. Recombinant virus VC2
was recovered after transfection of Vero cells. Double deletions
within the gK and UL20 genes were confirmed by capillary DNA
sequencing. The absence of any other mutations within all HSV-1
structural proteins was confirmed by NGS sequencing using Ion
Torrent Personal Genome Machine. Stocks of VC2, HSV-1
(McKrae), and HSV-2 (G), were grown and titrated in Vero cells.

Figure 7. In-vitro analysis of humoral immune response. (A)
Colorimetric ELISA based analysis of HSV-1 reactive polyclonal IgG
produced 21 days post vaccination n = 20. Statistical comparison
conducted by SAS using the T test Procedure. Bars represent the 95%
confidence interval about the mean (B) Titration of serum neutralizing
fixed PFU of HSV-1 (McKrae) normalized to a no serum control n = 5.
Significant reduction in PFU observed 1:160, 1:80, 1:40, and 1:20
dilutions of the sera. Statistical comparison conducted by SAS using The
Mixed Procedure and Differences in Least Squares Means. Bars
represent the 95% confidence interval about the mean. (C) Cross
reactive neutralization of HSV-1 (McKrae) and HSV-2 (G) at a 1:20
dilution of sera from vaccinated and mock inoculated mice. Percent
neutralization normalized to no serum controls. Statistical comparison
conducted by SAS using The Mixed Procedure and Differences in Least
Squares Means. Bars represent the 95% confidence interval about the
mean. Significant differences noted as * p#0.05, ** p#0.01, or *** p#
0.0001.
doi:10.1371/journal.pone.0109890.g007
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Figure 8. In-vitro analysis of cellular immune response. (A) Proliferation of CD4+ vs CD8+ T cells from mice which received the vaccine and
mice which were mock injected and stimulated with pooled HSV-1 or HSV-2 peptides. (B–F) CBA analysis of secreted cytokine concentration in cell
culture supernatant from T cell proliferation assay. Statistical comparison conducted by SAS using The Mixed Procedure and Differences in Least
Squares Means. Bars represent the 95% confidence interval about the mean. Significant differences noted as * p#0.05, ** p#0.01, or *** p#0.0001.
doi:10.1371/journal.pone.0109890.g008

Next generation genomic DNA sequencing

VC2 replication and entry characteristics

DNA sequencing of the HSV-1 VC2 mutant virus was
performed using the Ion Torrent Personal Genome Machine
(PGM) and the 316 sequencing Chip (Life Technologies). Two
independent total DNA samples derived from infected Vero cells
and from partially purified virions were isolated using the
PureLink Genomic DNA mini Kit (Invitrogen). The Ion Xpress
Plus Fragment Library Kit (Life Technologies) was used to prepare
high-quality fragment libraries from approximately 1 mg of total
DNA. Template-positive Ion Sphere Particles (ISPs) containing
clonally amplified DNA were produced using the Ion OneTouch
200 Template Kit v2 DL (for 200 base-read libraries) with the Ion
OneTouch instrument. The Ion OneTouch ES instrument was
used to enrich ISPs intended for the Ion PGM System using the
Ion PGM 200 Sequencing Kit.

Replication kinetics assay was performed on confluent monolayers of green African monkey kidney cells (Vero) in 12 well
plates. Infections with either HSV-1 (F) or mutant virus VC2 were
performed at an MOI of 0.1 and 5. Inoculated plates were placed
at 4uC for 1 hour to allow for virion attachment and returned to
37uC for another hour to allow for entry. Plates were then washed
with 16 Phosphate Buffered Saline and a final volume of 1 mL of
complete DMEM 10% heat inactivated FBS applied to each.
Plates were frozen at 280uC until titrated for the following times
post infection; 0, 2, 4, 6, 9, 12, 18, 24, and 36 hours. Samples were
titrated on confluent monolayers of Vero cells. Infected cell
cultures were fixed 48 hpi using formalin-acetic acid- alcohol
(FAA) and stained with crystal violet. Plaques were counted using a
light microscope and virion titers expressed as PFU/mL were
derived for each sample.
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with 70% ethanol, and resuspended to a final volume of 50 mL
nuclease free water.

Entry assay into CHO cells expressing known HSV-1 entry
receptors was conducted as described in Chowdhury et al. [62].
Plaque morphology assays were conducted on confluent monolayers of Vero cells in 6-well formats. Virus was serial diluted until
single isolated plaques were visible. Immunohistochemistry was
performed using polyclonal rabbit anit-HSV-1 primary antibody
(Dako, Denmark), polyclonal goat anti-rabbit immunoglobulins
HRP conjugated secondary antibody (Dako, Denmark), and
visualized using Vector NovaRED Substrate Kit (Vector,
Burlingame, CA). Substrate was allowed to develop until sufficient
coloration for microscopic imagery.

Polychromatic flow cytometry and analysis
Cryopreserved Cells were resuspended at a concentration of 106
cells/mL and labeled with the membrane stain Carboxyfluorescein succinimidyl ester (CFSE). Labeled cells were then cultured
at a concentration of 105 cells/well in a 96 well U-bottom plate
and incubated at 37uC and 5% CO2 for 7 days in the presence of
pooled peptides specific to either HSV-1 or HSV-2 at a
concentration of 10 mg/mL Cells were then stained with
polyclonal anti-mouse CD4 antibody conjugated to PE (BD
Biosciences) and polyclonal anti-mouse CD8a antibody conjugated to APC (BD Biosciences). Proliferation of labeled T cell subsets
was assessed using an Accuri C6 personal flow cytometer.
Unstimulated CFSE-labeled splenocytes were used to establish
the CFSEbright population and to define the gating used to quantify
CFSEdim (proliferating) T cells.
Supernatants from cultured spleenocytes were stored at 220uC
until analysis. Cytokine responses from cultured splenocytes were
analyzed using the BD Cytometric Bead Array (CBA) Mouse
Th1/Th2 Cytokine Kit (BD Biosciences, San Diego, CA) read
using a Bioplex analyzer (Bio-Rad, Hercules, CA) as per the
manufacturer’s instructions.

Safety and neurovirulence
Neurovirulence assessment was conducted by inoculation of 20
mice with 106 PFU either intranasall or intramuscularly with 10 in
each group. Mice were monitored daily for 20 days post
inoculation for the manifestation of disease. On day 21, mice
were sacrificed and trigeminal ganglia for intranasal inoculations
and dorsal root ganglia (for intramuscular inoculations) were
collected. Total tissue DNA was extracted using the Qiagen
DNeasy Blood and Tissue Kit (Qiagen) and viral genomes were
estimated using quantitative PCR.

Vaccination
All animal studies were carried out after the appropriate
approvals were obtained from the Louisiana State University
Institutional Animal Care and Use Committee. Six week old
female Balb/c mice (LSU DLAM Breeding Colony, Baton Rouge,
LA) were used in this study. Each mouse was identified with an ear
tag (National Band and Tag Company, KY, USA). Mice were
divided into two groups to receive either the vaccine or mock
inoculations. Eighty mice, 40 in each group, were mildly
anesthetized by inhalation of 2–3% isoflurane and administered
a single 100 mL intramuscular injection of either 16107 PFU of
VC2 or equivalent volume of conditioned media. Mice were then
observed daily collecting weight and clinical observations.

Challenge
On day 15 post vaccination mice were administered Depo
Provera (Upjohn, Kalamazoo, MI) via intra muscular injection as
described previously Iyer et al. [54] On the day of challenge mice
vaginas were swabbed with sterile polystyrine applicator tips
dipped in 100 mL DMEM containing 50 mg/L primocin. 106
plaque forming units of highly virulent HSV-1 (McKrae) or HSV2 (G) were instilled in the vaginal vault and mice were closely
monitored daily for clinical manifestation of disease recording
daily weight and clinical scores. Mice were scored on a scale of 0–6
(0 = no disease, 1 = ruffled fur and generalized morbidity, 2 = mild
genital erythema and edema, 3 = moderate genital inflammation,
4 = genital inflammation with purulent discharge, 5 = hind limb
paralysis, 6 = death). On the day an animal succumbed to disease,
or on the day of sacrifice pertinent tissues were collected and
preserved in 10% neutral buffered formalin (American Mastertech, Lodi, CA).

Tissue collection and analysis
On day 21 post vaccination 20 mice from each group were
anesthetized by inhalation of 2–3% isoflurane and bled via cardiac
stick. Maximum volume of blood was collected and mice were
euthanized by cervical dislocation. Blood was allowed to clot at
4uC overnight in 5mL falcon tubes (Becton Dickinson, Franklin
lakes, NJ) and serum collected into 2 mL Sarstedt Screw Cap
Micro Tubes (Sarstedt inc, Newton, NC) and stored at 220uC
until use. Spleens were excised from euthanized animals, minced
and passed through a 10 mm nylon mesh cell strainer (Fisher
Scientific) in Hank’s Balanced Salt Solution. Cell suspensions were
then pelleted by centrifugation at 300 6g for 5 minutes and frozen
in 5% DMSO Heat Inactivated Fetal Bovine Serum at a
concentration of 107 cells/ml. Cells were stored in liquid nitrogen
until use.
Dorsal root ganglia were excised as described in Pazyra-Murphy
et al. [49] Briefly, the peritoneal cavity of the mouse was opened
and eviscerated of all organs. Tissues covering the ventral portion
of the spine were removed. Dissection was conducted under
magnification with a dissecting microscope. Carefully with curved
scissors the spinal column was cut medially and scissors inserted
into the subarachnoid space to make two lateral cuts along the
length of the spine. Spinal chords were removed with attached
dorsal root ganglia. DNA was extracted using the Qiagen DNeasy
Blood and Tissue kit (Qiagen Sciences, Maryland, USA) as per the
manufactures instructions and DNA was precipitated with an
equal volume of isopropenol plus 0.3 M sodium acetate, washed
PLOS ONE | www.plosone.org

Latency reactivation
Reactivation was conducted as described in Cooke et al [63].
Briefly, on day 100 post challenge vaccinated mice, which had
already survived challenge, received a series of intravenous
injections. First 5 mg of cyclophosphamide (Baxter, Deerfield,
IL) followed 24 hours later by 0.2 mg of dexamethasone (Butler
Schein, Dublin, OH) injected via the same route. Mice were
monitored daily for any clinical manifestation of disease. Vaginal
swab samples were taken daily for 5 days prior to and post
administration of cyclophosphamide and dexamethasone and
assayed by plaque assay for the presence of virus, as described
under the virus shedding heading. Surviving mice were sacrificed
for analysis of excised nervous tissue for the presence of viral DNA.

Quantitative PCR
Dorsal root ganglia (DRG) were resected from vaccinated mice
and unvaccinated controls, challenged with either HSV1 McKrae
or HSV2-G. The DRGs were vigorously aspirated and DNA was
extracted using the Qiagen DNeasy Blood & Tissue Kit as per the
manufacturer’s instructions. The eluted DNA was quantified using
10
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a Nanodrop 1000 spectrophotometer. Equal amounts of DNA
from each sample were used to perform quantitative real-time
PCR analysis on an Applied Biosystems 7900HT Fast Real-Time
PCR System. Viral DNA from purified HSV-1 (McKrae) and
HSV-2(G) were used as positive controls. The following primer/
probe combinations were used to specifically detect HSV-1
(McKrae) or HSV-2(G) (see also Table 1): 1) HSV1gDFP
(ACGTACCTGCGGCTCGTGAAGA); 2) HSV1 Probe (Fam –
AGCCAAGGGCTCCTGTAAGTACGCCCT – Tamra); 3)
HSV1 gD RP (TCACCCCCTGCTGGTAG GCC); 4)
HSV2gDFP (CCGCGGGTACGTACCTGCGGCTAG); 5)
HSV2 Probe (HEX - GGCCC GCGC/ZEN/CTCCTGCAAGTACGCTCT
–
IABkFQ);
6)
HSV2
gD
RP
(GCCCTGTTGGTAGGCCTT CGAGGTG). To determine
the sensitivity of the qPCR assay, HSV-1 and HSV-2 genomic
DNA were quantified and their respective molar concentrations
was calculated using the formula:– {mgDNA 6 (pmol/660) 6 (106
pg/1mg) 6 (1/N) = pmol DNA, where N = number of nucleotides}. Ten-fold serial dilutions ranging from 105–100.1 molecules
were used as template samples in Taqman PCR reactions, and
water was used a no template control. qPCR was performed on
the Applied biosystems 7900HT Fast Real-Time PCR System.
HSV target DNA was detected at the lowest dilution (2.761028 mg
of DNA) containing 3 copies per ml. No viral DNA was detected in
the no template control sample. The linear range of detection
ranged from 3 to 106 viral DNA copies with a mock-vaccinated
mice exhibiting more than 106 viral DNA copies per sample.

wells were covered with 1% DMEM methylcellulose containing
1% FBS and 50 mg/L Primocin. Plates were then incubated at
37uC with 5% CO2 for 36–48 hours until visible plaques had
formed. Plates were then fixed with FAA and stained with crystal
violet. Plaques were counted at dilutions yielding greater than 20
plaques per well.

Virus shedding

Acknowledgments

Antibody ELISA and serum neutralization
Relative anti-HSV-1 IgG serum concentrations were quantified
using commercially available Mouse/Rat HSV-1 IgG ELISA
(Calbiotech, Spring Valley, CA). Serum collected on day 21 was
used to neutralize 50 mL of stock HSV-1 Mckrae and HSV-2 G
containing approximately 56105 and 36103 PFU, respectively.
Serum was first diluted 1:10 in complete DMEM containing 10%
heat inactivated FBS. Diluted serum was then two fold serial
diluted to 1:160. 50 mL of stock virus was then added to each
dilution of serum, 50 mL each, to a total volume of 100 mL.
Addition of virus made serum dilutions 1:20, 1:40, 1:80, 1:160,
and 1:320. Serum virus mixtures were then placed on a rocker at
room temperature for 1 hour and frozen at 280uC until titration
on Vero cells.

Supporting Information
Table S1 Table of epitopes. Table of peptides used in pools

for spleenocyte stimulation assays.
(DOCX)

On the day of challenge, before administration of virus, and
daily following innoculation, vaginas were swabbed with sterile
polystyrene applicator tips dipped in 100 uL DMEM containing
50 mg/L Primocin (InvivoGen, San Diego, CA). Swab samples
were stored at 280uC until titration. Titration of swab samples
was conducted on confluent monolayers of Vero cells. Samples
were resuspended in 900 ml of DMEM +50 mg/L Primocin for an
initial dilution of 1021 and diluted in 10 fold increments out to
1026. 250 mL of each dilution was plated in duplicate and
incubated at 24uC for 1 hour. Dilutions were then aspirated and

The authors acknowledge the expert biostatistical assistance provided by
Mr. Michael Kearney and Dr. Rebecca Christofferson of the LSU School
of Veterinary Medicine.

Author Contributions
Conceived and designed the experiments: BS KGK. Performed the
experiments: JS VNC RS ASC AS. Analyzed the data: JDW KGK.
Contributed to the writing of the manuscript: BS KGK RS JDW. Primarily
responsible for executing all animal vaccine experiments: BS JS.

References
10. Wald A, Link K (2002) Risk of human immunodeficiency virus infection in
herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis
185: 45–52.
11. Sartori E, Calistri A, Salata C, Del Vecchio C, Palu G, et al. (2011) Herpes
simplex virus type 2 infection increases human immunodeficiency virus type 1
entry into human primary macrophages. Virol J 8: 166.
12. Brown JM, Wald A, Hubbard A, Rungruengthanakit K, Chipato T, et al. (2007)
Incident and prevalent herpes simplex virus type 2 infection increases risk of
HIV acquisition among women in Uganda and Zimbabwe. AIDS 21: 1515–
1523.
13. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, et al. (2006)
Herpes simplex virus 2 infection increases HIV acquisition in men and women:
systematic review and meta-analysis of longitudinal studies. AIDS 20: 73–83.
14. Freeman EE, White RG, Bakker R, Orroth KK, Weiss HA, et al. (2009)
Population-level effect of potential HSV2 prophylactic vaccines on HIV
incidence in sub-Saharan Africa. Vaccine 27: 940–946.
15. Johnston C, Koelle DM, Wald A (2014) Current status and prospects for
development of an HSV vaccine. Vaccine 32: 1553–1560.
16. Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, et al. (2014) Toward
global prevention of sexually transmitted infections (STIs): The need for STI
vaccines. Vaccine 32: 1527–1535.
17. Blank H, Haines HG (1973) Experimental human reinfection with herpes
simplex virus. J Invest Dermatol 61: 223–225.
18. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, et al. (1998)
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of
HSV-specific cytotoxic T lymphocytes. J Clin Invest 101: 1500–1508.
19. Milligan GN, Bernstein DI, Bourne N (1998) T lymphocytes are required for
protection of the vaginal mucosae and sensory ganglia of immune mice against
reinfection with herpes simplex virus type 2. J Immunol 160: 6093–6100.

1. Bradley H, Markowitz LE, Gibson T, McQuillan GM (2014) Seroprevalence of
herpes simplex virus types 1 and 2–United States, 1999–2010. J Infect Dis 209:
325–333.
2. Hofstetter AM, Rosenthal SL, Stanberry LR (2014) Current thinking on genital
herpes. Curr Opin Infect Dis 27: 75–83.
3. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, et al. (2011) Genital
shedding of herpes simplex virus among symptomatic and asymptomatic persons
with HSV-2 infection. JAMA 305: 1441–1449.
4. Mertz GJ (2008) Asymptomatic shedding of herpes simplex virus 1 and 2:
implications for prevention of transmission. J Infect Dis 198: 1098–1100.
5. Roberts CM, Pfister JR, Spear SJ (2003) Increasing proportion of herpes simplex
virus type 1 as a cause of genital herpes infection in college students. Sex Transm
Dis 30: 797–800.
6. Anuradha K, Singh HM, Gopal KV, Rama Rao GR, Ramani TV, et al. (2008)
Herpes simplex virus 2 infection: a risk factor for HIV infection in heterosexuals.
Indian J Dermatol Venereol Leprol 74: 230–233.
7. Mugo N, Dadabhai SS, Bunnell R, Williamson J, Bennett E, et al. (2011)
Prevalence of herpes simplex virus type 2 infection, human immunodeficiency
virus/herpes simplex virus type 2 coinfection, and associated risk factors in a
national, population-based survey in Kenya. Sex Transm Dis 38: 1059–1066.
8. Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, et al.
(2003) Recent herpes simplex virus type 2 infection and the risk of human
immunodeficiency virus type 1 acquisition in India. J Infect Dis 187: 1513–1521.
9. Renzi C, Douglas JM Jr., Foster M, Critchlow CW, Ashley-Morrow R, et al.
(2003) Herpes simplex virus type 2 infection as a risk factor for human
immunodeficiency virus acquisition in men who have sex with men. J Infect Dis
187: 19–25.

PLOS ONE | www.plosone.org

11

October 2014 | Volume 9 | Issue 10 | e109890

Live-Attenuated Vaccine for Genital Herpes

48. Augustinova H, Hoeller D, Yao F (2004) The dominant-negative herpes simplex
virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine
against wild-type HSV-1 infection in mice. J Virol 78: 5756–5765.
49. Murphy CG, Lucas WT, Means RE, Czajak S, Hale CL, et al. (2000) Vaccine
protection against simian immunodeficiency virus by recombinant strains of
herpes simplex virus. J Virol 74: 7745–7754.
50. Watanabe D, Brockman MA, Ndung’u T, Mathews L, Lucas WT, et al. (2007)
Properties of a herpes simplex virus multiple immediate-early gene-deleted
recombinant as a vaccine vector. Virology 357: 186–198.
51. Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, et al. (2010)
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy
and cisplatin in untreated stage III/IV squamous cell cancer of the head and
neck. Clin Cancer Res 16: 4005–4015.
52. David AT, Baghian A, Foster TP, Chouljenko VN, Kousoulas KG (2008) The
herpes simplex virus type 1 (HSV-1) glycoprotein K(gK) is essential for viral
corneal spread and neuroinvasiveness. Curr Eye Res 33: 455–467.
53. David AT, Saied A, Charles A, Subramanian R, Chouljenko VN, et al. (2012) A
herpes simplex virus 1 (McKrae) mutant lacking the glycoprotein K gene is
unable to infect via neuronal axons and egress from neuronal cell bodies. MBio
3: e00144–00112.
54. Iyer AV, Pahar B, Chouljenko VN, Walker JD, Stanfield B, et al. (2013) Single
dose of Glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice
against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T
cell memory immune responses. Virol J 10: 317.
55. Saied AA, Chouljenko VN, Subramanian R, Kousoulas KG (2014) A replication
competent HSV-1(McKrae) with a mutation in the amino-terminus of
glycoprotein K (gK) is unable to infect mouse trigeminal ganglia after cornea
infection. Curr Eye Res 39: 596–603.
56. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y (2003)
Construction of an excisable bacterial artificial chromosome containing a fulllength infectious clone of herpes simplex virus type 1: viruses reconstituted from
the clone exhibit wild-type properties in vitro and in vivo. J Virol 77: 1382–
1391.
57. Chouljenko VN, Iyer AV, Chowdhury S, Chouljenko DV, Kousoulas KG
(2009) The amino terminus of herpes simplex virus type 1 glycoprotein K (gK)
modulates gB-mediated virus-induced cell fusion and virion egress. J Virol 83:
12301–12313.
58. Lee HC, Chouljenko VN, Chouljenko DV, Boudreaux MJ, Kousoulas KG
(2009) The herpes simplex virus type 1 glycoprotein D (gD) cytoplasmic terminus
and full-length gE are not essential and do not function in a redundant manner
for cytoplasmic virion envelopment and egress. J Virol 83: 6115–6124.
59. Kim IJ, Chouljenko VN, Walker JD, Kousoulas KG (2013) Herpes simplex virus
1 glycoprotein M and the membrane-associated protein UL11 are required for
virus-induced cell fusion and efficient virus entry. J Virol 87: 8029–8037.
60. Chouljenko VN, Iyer AV, Chowdhury S, Kim J, Kousoulas KG (2010) The
herpes simplex virus type 1 UL20 protein and the amino terminus of
glycoprotein K (gK) physically interact with gB. J Virol 84: 8596–8606.
61. Foster TP, Chouljenko VN, Kousoulas KG (2008) Functional and physical
interactions of the herpes simplex virus type 1 UL20 membrane protein with
glycoprotein K. J Virol 82: 6310–6323.
62. Chowdhury S, Chouljenko VN, Naderi M, Kousoulas KG (2013) The amino
terminus of herpes simplex virus 1 glycoprotein K is required for virion entry via
the paired immunoglobulin-like type-2 receptor alpha. J Virol 87: 3305–3313.
63. Cook SD, Paveloff MJ, Doucet JJ, Cottingham AJ, Sedarati F, et al. (1991)
Ocular herpes simplex virus reactivation in mice latently infected with latencyassociated transcript mutants. Invest Ophthalmol Vis Sci 32: 1558–1561.
64. Foster TP, Melancon JM, Olivier TL, Kousoulas KG (2004) Herpes simplex
virus type 1 glycoprotein K and the UL20 protein are interdependent for
intracellular trafficking and trans-Golgi network localization. J Virol 78: 13262–
13277.
65. Kim IJ, Saied AA, Chouljenko VN, Subramanian R, Kousoulas KG (2014)
Functional Hierarchy of Herpes Simplex Virus Type-1 Membrane Proteins in
Corneal Infection and Virus Transmission to Ganglionic Neurons. Curr Eye Res
(In Press).
66. Allen SJ, Mott KR, Ghiasi H (2014) Overexpression of herpes simplex virus
glycoprotein K (gK) alters expression of HSV receptors in ocularly-infected
mice. Invest Ophthalmol Vis Sci 55: 2442–2451.
67. Allen SJ, Mott KR, Ljubimov AV, Ghiasi H (2010) Exacerbation of corneal
scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+
CD25+ T cells in corneas of ocularly infected mice. Virology 399: 11–22.
68. Ghiasi H, Perng GC, Nesburn AB, Wechsler SL (2000) Antibody-dependent
enhancement of HSV-1 infection by anti-gK sera. Virus Res 68: 137–144.
69. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL, et al.
(2009) The role of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex
virus on virus replication and pathogenicity. Invest Ophthalmol Vis Sci 50:
2903–2912.
70. Mott KR, Perng GC, Osorio Y, Kousoulas KG, Ghiasi H (2007) A recombinant
herpes simplex virus type 1 expressing two additional copies of gK is more
pathogenic than wild-type virus in two different strains of mice. J Virol 81:
12962–12972.
71. Kousoulas KG, Huo B, Pereira L (1988) Antibody-resistant mutations in crossreactive and type-specific epitopes of herpes simplex virus 1 glycoprotein B map
in separate domains. Virology 166: 423–431.

20. Schiffer JT, Corey L (2013) Rapid host immune response and viral dynamics in
herpes simplex virus-2 infection. Nat Med 19: 280–290.
21. Wakim LM, Jones CM, Gebhardt T, Preston CM, Carbone FR (2008) CD8(+)
T-cell attenuation of cutaneous herpes simplex virus infection reduces the
average viral copy number of the ensuing latent infection. Immunol Cell Biol 86:
666–675.
22. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, et al. (2007) Virus-specific
CD8+ T cells accumulate near sensory nerve endings in genital skin during
subclinical HSV-2 reactivation. J Exp Med 204: 595–603.
23. Dudley KL, Bourne N, Milligan GN (2000) Immune protection against HSV-2
in B-cell-deficient mice. Virology 270: 454–463.
24. St Leger AJ, Hendricks RL (2011) CD8+ T cells patrol HSV-1-infected
trigeminal ganglia and prevent viral reactivation. J Neurovirol 17: 528–534.
25. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, et al. (2011) Transfer of
IgG in the female genital tract by MHC class I-related neonatal Fc receptor
(FcRn) confers protective immunity to vaginal infection. Proc Natl Acad
Sci U S A 108: 4388–4393.
26. Morrison LA, Zhu L, Thebeau LG (2001) Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in
the presence of immune T cells. J Virol 75: 1195–1204.
27. Seppanen M, Meri S, Notkola IL, Seppala IJ, Hiltunen-Back E, et al. (2006)
Subtly impaired humoral immunity predisposes to frequently recurring genital
herpes simplex virus type 2 infection and herpetic neuralgia. J Infect Dis 194:
571–578.
28. Dropulic LK, Cohen JI (2012) The challenge of developing a herpes simplex
virus 2 vaccine. Expert Rev Vaccines 11: 1429–1440.
29. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus
immunobiology and vaccine research. Clin Microbiol Rev 16: 96–113.
30. Roth K, Ferreira VH, Kaushic C (2013) HSV-2 vaccine: current state and
insights into development of a vaccine that targets genital mucosal protection.
Microb Pathog 58: 45–54.
31. Rupp R, Bernstein DI (2008) The potential impact of a prophylactic herpes
simplex vaccine. Expert Opin Emerg Drugs 13: 41–52.
32. Zhu XP, Muhammad ZS, Wang JG, Lin W, Guo SK, et al. (2014) HSV-2
vaccine: current status and insight into factors for developing an efficient
vaccine. Viruses 6: 371–390.
33. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy
results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34–43.
34. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, et al. (2014)
Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated
Women. J Infect Dis 209: 828–836.
35. Awasthi S, Friedman HM (2014) A paradigm shift: vaccine-induced antibodies
as an immune correlate of protection against herpes simplex virus type 1 genital
herpes. J Infect Dis 209: 813–815.
36. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ (1998) The
genome sequence of herpes simplex virus type 2. J Virol 72: 2010–2021.
37. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM (2008) A
replication-competent, neuronal spread-defective, live attenuated herpes simplex
virus type 1 vaccine. J Virol 82: 8431–8441.
38. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live attenuated
herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate
defective in neuronal spread. J Virol 86: 4586–4598.
39. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, et al. (2005)
Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2
vaccine in guinea pigs. Vaccine 23: 5424–5431.
40. van Lint AL, Torres-Lopez E, Knipe DM (2007) Immunization with a
replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus
1 infection and prevents ocular disease. Virology 368: 227–231.
41. Dudek T, Mathews LC, Knipe DM (2008) Disruption of the U(L)41 gene in the
herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and
protective capacity in a murine model of genital herpes. Virology 372: 165–175.
42. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, et al. (2008)
Comparison of immunogenicity and protective efficacy of genital herpes vaccine
candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea
pigs. Vaccine 26: 4034–4040.
43. Da Costa XJ, Morrison LA, Knipe DM (2001) Comparison of different forms of
herpes simplex replication-defective mutant viruses as vaccines in a mouse model
of HSV-2 genital infection. Virology 288: 256–263.
44. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, et al. (2011) A
live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection
against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6:
e17748.
45. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F (2011)
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against
HSV-2 infection in mice. J Virol 85: 5036–5047.
46. Brans R, Akhrameyeva NV, Yao F (2009) Prevention of genital herpes simplex
virus type 1 and 2 disease in mice immunized with a gD-expressing dominantnegative recombinant HSV-1. J Invest Dermatol 129: 2470–2479.
47. Brans R, Yao F (2010) Immunization with a dominant-negative recombinant
Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in
guinea pigs. BMC Microbiol 10: 163.

PLOS ONE | www.plosone.org

12

October 2014 | Volume 9 | Issue 10 | e109890

Live-Attenuated Vaccine for Genital Herpes

72. Pereira L, Klassen T, Baringer JR (1980) Type-common and type-specific
monoclonal antibody to herpes simplex virus type 1. Infect Immun 29: 724–732.
73. Chentoufi AA, Binder NR, Berka N, Durand G, Nguyen A, et al. (2008)
Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes
simplex virus glycoprotein B. J Virol 82: 11792–11802.
74. Coleman JL, Shukla D (2013) Recent advances in vaccine development for
herpes simplex virus types I and II. Hum Vaccin Immunother 9: 729–735.

PLOS ONE | www.plosone.org

75. Dervillez X, Gottimukkala C, Kabbara KW, Nguyen C, Badakhshan T, et al.
(2012) Future of an ‘‘Asymptomatic’’ T-cell Epitope-Based Therapeutic Herpes
Simplex Vaccine. Future Virol 7: 371–378.
76. Shin H, Iwasaki A (2012) A vaccine strategy that protects against genital herpes
by establishing local memory T cells. Nature 491: 463–467.
77. Hirt B (1967) Selective extraction of polyoma DNA from infected mouse cell
cultures. J Mol Biol 26: 365–369.

13

October 2014 | Volume 9 | Issue 10 | e109890

